Company news

AstraZeneca PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Tagrisso plus chemo improved PFS in lung cancer

May 17, 2023

Farxiga extended in the US for heart failure

May 9, 2023

ODAC vote on Lynparza combo in prostate cancer

May 2, 2023

Board Committee Changes

April 27, 2023

Update to arrangements with Sobi and Sanofi

April 11, 2023

Lynparza + Imfinzi met endpoint in ovarian cancer

April 5, 2023

Ultomiris recommended for NMOSD EU approval

April 3, 2023

AstraZeneca completes KYM agreement for CMG901

March 30, 2023

Imfinzi improved EFS in resectable lung cancer

March 9, 2023

Enhertu DESTINY-PanTumor02 shows positive results

March 6, 2023

AstraZeneca prices a $2.25bn bond offering

March 1, 2023

AstraZeneca prices a EUR1.5bn bond offering

February 24, 2023

AstraZeneca acquires CinCor for cardiorenal asset

February 24, 2023

AstraZeneca enters agreement with KYM for CMG901

February 23, 2023

Update on Evusheld US EUA

January 26, 2023

Acquisition of Neogene Therapeutics completed

January 16, 2023

Airsupra (PT027) approved in US for asthma

January 11, 2023

AstraZeneca acquire CinCor for cardiorenal asset

January 9, 2023

Calquence Japan approval for treatment-naïve CLL

December 28, 2022

Imfinzi, Imjudo approved in Japan for 3 cancers

December 28, 2022

Lynparza approved in EU for prostate cancer

December 21, 2022

Imfinzi approved in EU for biliary tract cancer

December 21, 2022

Enhertu recommended for EU approval in HER2-low BC

December 19, 2022

Enhertu approved in EU for gastric cancer

December 19, 2022

Imfinzi + Imjudo recommended for approvals in EU

December 19, 2022

Update on Imfinzi PEARL trial

December 19, 2022

Forxiga CHMP opinion for symptomatic chronic HF

December 19, 2022

Update on US review of Lynparza PROpel sNDA

December 15, 2022

Capivasertib PFS in HR-positive breast cancer

December 8, 2022

AstraZeneca announces sale of West Chester site

November 30, 2022

AstraZeneca to acquire Neogene Therapeutics

November 29, 2022

Enhertu recommended for EU approval in gastric

November 14, 2022

Imfinzi recommended for approval in the EU for BTC

November 14, 2022

Lynparza combo recommended in the EU for mCRPC

November 14, 2022

Imfinzi + Imjudo approved in US for lung cancer

November 11, 2022

YTD and Q3 2022 Results

November 10, 2022

FDA Advisory Committee recommends PT027 in asthma

November 9, 2022

Beyfortus (nirsevimab) approved in EU

November 4, 2022

Capivasertib Phase III trial met primary endpoints

October 26, 2022

Update on MESSINA Phase III trial

October 25, 2022

Imfinzi + Imjudo approved in advanced liver cancer

October 24, 2022

Koselugo approved in Japan for NF1

September 27, 2022

Tezspire approved in Japan for severe asthma

September 27, 2022

Ultomiris approved in EU for gMG

September 23, 2022

Lynparza approved in China for ovarian cancer

September 22, 2022

Tezspire approved in the EU for severe asthma

September 21, 2022

Evusheld approved in EU for COVID-19 treatment

September 20, 2022

Danicopan Phase III trial met primary endpoint

September 16, 2022

Evusheld positive CHMP opinion in EU

September 16, 2022

Nirsevimab recommended for approval in EU by CHMP

September 16, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 242 decks. Every deck is listed under its year.